Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review.
Jessica D RichStephen M ClarkYuri FedoriwValerie JewellsWilliam WoodChristopher DittusPublished in: Clinical case reports (2019)
Central nervous system (CNS)-relapsed mantle cell lymphoma (MCL) is a rare, aggressive non-Hodgkin lymphoma without a standard treatment. Ibrutinib has shown promising results for inducing remission in other non-Hodgkin lymphomas and may be considered as successful treatment for CNS-relapsed MCL in the future as well.
Keyphrases
- hodgkin lymphoma
- stem cells
- acute lymphoblastic leukemia
- acute myeloid leukemia
- multiple myeloma
- diffuse large b cell lymphoma
- blood brain barrier
- chronic lymphocytic leukemia
- stem cell transplantation
- disease activity
- cerebrospinal fluid
- ulcerative colitis
- bone marrow
- systemic lupus erythematosus
- current status
- combination therapy
- mesenchymal stem cells
- replacement therapy
- cell therapy